| Antihistamines |
| Antiinfective agents |
| Antineoplastic agents |
| Autonomic drugs |
| Blood derivatives |
| Blood formation and coagulation |
| Cardiovascular drugs |
| CNS agents |
| Diagnostic agents |
| Electrolytic, caloric and water balance |
| Enzymes |
| Gastrointestinal drugs |
| Gold compounds |
| Heavy metal antagonists |
| Hormones/synthetic substitutes |
| Local anesthetics |
| Oxytocics |
| Radioactive agents |
| Serums toxoids, vaccines |
| Skin and mucous membrane agents |
| Smooth muscle relaxants |
| Vitamins |
| Unclassified therapeutic agents |
(3) The schedule of drugs in subsection (2) of this section shall not include the following unless the delegator is physically present in the immediate area where the drug is administered:
(a) Any controlled substances as defined in RCW
69.50.101 (1)(d); or
(b) Any experimental drug; or
(c) Any cancer chemotherapy agent.
[Statutory Authority: RCW
18.135.030 and 2009 c 43. WSR 10-19-044, § 246-826-200, filed 9/13/10, effective 10/14/10. Statutory Authority: RCW
43.70.040. WSR 91-02-049 (Order 121), recodified as § 246-826-200, filed 12/27/90, effective 1/31/91. Statutory Authority: RCW
18.135.030. WSR 87-23-022 (Order PM 689), § 308-175-130, filed 11/12/87.]